145 filings
8-K
ZYNE
Zynerba Pharmaceuticals, Inc.
11 Oct 23
Completion of Acquisition or Disposition of Assets
8:17am
8-K
ZYNE
Zynerba Pharmaceuticals, Inc.
29 Aug 23
Submission of Matters to a Vote of Security Holders
4:05pm
8-K
ZYNE
Zynerba Pharmaceuticals, Inc.
14 Aug 23
Tender and Support Agreement
7:42am
8-K
ZYNE
Zynerba Pharmaceuticals, Inc.
14 Jun 23
Submission of Matters to a Vote of Security Holders
4:05pm
8-K
ZYNE
Zynerba Pharmaceuticals, Inc.
15 May 23
Zynerba Pharmaceuticals Reports First Quarter 2023 Financial Results
7:05am
8-K
rm3ibw 45
4 May 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:06pm
8-K
021qyr8qx59sye4k
28 Mar 23
Zynerba Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights
7:38am
8-K
euclnooucuji
10 Mar 23
Regulation FD Disclosure
6:46pm
8-K
nyb brmdvprn
9 Jan 23
Other Events
7:30am
8-K
mxpe kr682x8itdsy
21 Dec 22
Zynerba Pharmaceuticals Announces Update on RECONNECT, the Pivotal Phase 3 Trial of Zygel™ in Fragile X Syndrome
7:15am
8-K
itzuo0xx
5 Dec 22
Other Events
8:30am
8-K
buhiy goezf4fapqc5
15 Nov 22
Other Events
7:45am
8-K
br73okiw7fsodrlbziaf
14 Nov 22
Zynerba Pharmaceuticals Reports Third Quarter 2022 Financial Results
7:35am
8-K
9a4poo pnei3
4 Nov 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:15pm
8-K
rvo611t
13 Sep 22
Other Events
7:30am
8-K
ua6jps3j1y9y7tll8 9k
10 Aug 22
Zynerba Pharmaceuticals Reports Second Quarter 2022 Financial Results and Operational Highlights
12:00am
8-K
qp9ijlu8
21 Jul 22
Entry into a Material Definitive Agreement
7:07am
8-K
s83ovw9a0h
22 Jun 22
Zynerba Pharmaceuticals Announces Positive Top Line Results from Open-Label Phase 2 INSPIRE Trial of Zygel™ in 22q11.2 Deletion Syndrome
6:00am
8-K
g6vin
16 Jun 22
Submission of Matters to a Vote of Security Holders
4:18pm
8-K
dcapo1lnrok afc52q
1 Jun 22
Zynerba Pharmaceuticals Presents Data on Zygel™ at the American Society of Clinical Psychopharmacology Annual Meeting
7:06am